The relationship between dopamine receptor blockade and cognitive performance in schizophrenia: a [11C]-raclopride PET study with aripiprazole

to related objects

Location: Deutsche Nationalbibliothek Frankfurt am Main

ISSN: 2158-3188

Extent: Online-Ressource

Language: Englisch

Notes: online resource.

Bibliographic citation: The relationship between dopamine receptor blockade and cognitive performance in schizophrenia: a [11C]-raclopride PET study with aripiprazole ; volume:8 ; number:1 ; day:24 ; month:4 ; year:2018 ; pages:1-7 ; date:12.2018
Translational Psychiatry ; 8, Heft 1 (24.4.2018), 1-7, 12.2018

Creator: Shin, Sangho

Contributor: Kim, Seoyoung
Seo, Seongho
Lee, Jae Sung
Howes, Oliver D.
Kim, Euitae
Kwon, Jun Soo
SpringerLink (Online service)

DOI: 10.1038/s41398-018-0134-6

URN: urn:nbn:de:101:1-2018062521215405038236

Rights: Der Zugriff auf das Objekt ist unbeschränkt möglich.

Last update: 15.08.2025, 7:32 AM CEST

Data provider

This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.

Show original at data provider

Associated

Shin, Sangho
Kim, Seoyoung
Seo, Seongho
Lee, Jae Sung
Howes, Oliver D.
Kim, Euitae
Kwon, Jun Soo
SpringerLink (Online service)

Other Objects (12)

Evaluation of dopamine D3 receptor occupancy by blonanserin using [11C]-(+)-PHNO in schizophrenia patients

Place of the partial dopamine receptor agonist aripiprazole in the management of schizophrenia in adults: a Delphi consensus study

Differences in autonomic nervous system activity between long-acting injectable aripiprazole and oral aripiprazole in schizophrenia

Relationship between subjective well-being and aripiprazole: an [11C]raclopride PET study

Binding kinetics of cariprazine and aripiprazole at the dopamine D3 receptor

Cost-Utility Analysis of Lurasidone Versus Aripiprazole in Adults with Schizophrenia

Effectiveness of aripiprazole once-monthly in schizophrenia patients pretreated with oral aripiprazole: a 6-month, real-life non-interventional study

Correction to: Effectiveness of aripiprazole once-monthly in schizophrenia patients pretreated with oral aripiprazole: a 6-month, real-life non-interventional study

Therapeutic reference range for aripiprazole in schizophrenia revised: a systematic review and metaanalysis

Therapeutic Reference Range for Aripiprazole in Schizophrenia Revised: a Systematic Review and Metaanalysis

Therapeutic reference range for aripiprazole in schizophrenia revised: a systematic review and metaanalysis

Treating symptomatic hyperprolactinemia in women with schizophrenia: presentation of the ongoing DAAMSEL clinical trial (Dopamine partial Agonist, Aripiprazole, for the Management of Symptomatic ELevated prolactin)

Evaluation of dopamine D3 receptor occupancy by blonanserin using [11C]-(+)-PHNO in schizophrenia patients

Place of the partial dopamine receptor agonist aripiprazole in the management of schizophrenia in adults: a Delphi consensus study

Differences in autonomic nervous system activity between long-acting injectable aripiprazole and oral aripiprazole in schizophrenia

Relationship between subjective well-being and aripiprazole: an [11C]raclopride PET study

Binding kinetics of cariprazine and aripiprazole at the dopamine D3 receptor

Cost-Utility Analysis of Lurasidone Versus Aripiprazole in Adults with Schizophrenia

Effectiveness of aripiprazole once-monthly in schizophrenia patients pretreated with oral aripiprazole: a 6-month, real-life non-interventional study

Correction to: Effectiveness of aripiprazole once-monthly in schizophrenia patients pretreated with oral aripiprazole: a 6-month, real-life non-interventional study

Therapeutic reference range for aripiprazole in schizophrenia revised: a systematic review and metaanalysis

Therapeutic Reference Range for Aripiprazole in Schizophrenia Revised: a Systematic Review and Metaanalysis

Therapeutic reference range for aripiprazole in schizophrenia revised: a systematic review and metaanalysis

Treating symptomatic hyperprolactinemia in women with schizophrenia: presentation of the ongoing DAAMSEL clinical trial (Dopamine partial Agonist, Aripiprazole, for the Management of Symptomatic ELevated prolactin)

Evaluation of dopamine D3 receptor occupancy by blonanserin using [11C]-(+)-PHNO in schizophrenia patients

Place of the partial dopamine receptor agonist aripiprazole in the management of schizophrenia in adults: a Delphi consensus study

Differences in autonomic nervous system activity between long-acting injectable aripiprazole and oral aripiprazole in schizophrenia

Relationship between subjective well-being and aripiprazole: an [11C]raclopride PET study

Binding kinetics of cariprazine and aripiprazole at the dopamine D3 receptor

Cost-Utility Analysis of Lurasidone Versus Aripiprazole in Adults with Schizophrenia

Effectiveness of aripiprazole once-monthly in schizophrenia patients pretreated with oral aripiprazole: a 6-month, real-life non-interventional study

Correction to: Effectiveness of aripiprazole once-monthly in schizophrenia patients pretreated with oral aripiprazole: a 6-month, real-life non-interventional study

Therapeutic reference range for aripiprazole in schizophrenia revised: a systematic review and metaanalysis

Therapeutic Reference Range for Aripiprazole in Schizophrenia Revised: a Systematic Review and Metaanalysis

Therapeutic reference range for aripiprazole in schizophrenia revised: a systematic review and metaanalysis

Treating symptomatic hyperprolactinemia in women with schizophrenia: presentation of the ongoing DAAMSEL clinical trial (Dopamine partial Agonist, Aripiprazole, for the Management of Symptomatic ELevated prolactin)

Cultural heritage institutions wishing to register will find more information here.

Fields marked * need to be filled in.

Username*

Please enter your username

Email*

Please enter your email address

Please do not fill this field

First name

Last name

Password*

Please enter your password

Confirm password*

Please enter the same password

I have read the terms of use and the privacy policy for the collection of personal data and accept them. *

This field is required.

I would like to subscribe to the newsletter of the Deutsche Digitale Bibliothek. See newsletter subscription info.

Account created

Your "My DDB" account has been successfully created. Before you can log in to your account, you must click the confirmation link in the message we just sent to the email address you provided.

The relationship between dopamine receptor blockade and cognitive performance in schizophrenia: a [11C]-raclopride PET study with aripiprazole

Object Details

References and Relationships

Contributors, Places and Time

Further information

Data provider

Associated

Other Objects (12)

Evaluation of dopamine D3 receptor occupancy by blonanserin using [11C]-(+)-PHNO in schizophrenia patients

Place of the partial dopamine receptor agonist aripiprazole in the management of schizophrenia in adults: a Delphi consensus study

Differences in autonomic nervous system activity between long-acting injectable aripiprazole and oral aripiprazole in schizophrenia

Relationship between subjective well-being and aripiprazole: an [11C]raclopride PET study

Binding kinetics of cariprazine and aripiprazole at the dopamine D3 receptor

Cost-Utility Analysis of Lurasidone Versus Aripiprazole in Adults with Schizophrenia

Effectiveness of aripiprazole once-monthly in schizophrenia patients pretreated with oral aripiprazole: a 6-month, real-life non-interventional study

Correction to: Effectiveness of aripiprazole once-monthly in schizophrenia patients pretreated with oral aripiprazole: a 6-month, real-life non-interventional study

Therapeutic reference range for aripiprazole in schizophrenia revised: a systematic review and metaanalysis

Therapeutic Reference Range for Aripiprazole in Schizophrenia Revised: a Systematic Review and Metaanalysis

Therapeutic reference range for aripiprazole in schizophrenia revised: a systematic review and metaanalysis

Treating symptomatic hyperprolactinemia in women with schizophrenia: presentation of the ongoing DAAMSEL clinical trial (Dopamine partial Agonist, Aripiprazole, for the Management of Symptomatic ELevated prolactin)

Evaluation of dopamine D3 receptor occupancy by blonanserin using [11C]-(+)-PHNO in schizophrenia patients

Place of the partial dopamine receptor agonist aripiprazole in the management of schizophrenia in adults: a Delphi consensus study

Differences in autonomic nervous system activity between long-acting injectable aripiprazole and oral aripiprazole in schizophrenia

Relationship between subjective well-being and aripiprazole: an [11C]raclopride PET study

Binding kinetics of cariprazine and aripiprazole at the dopamine D3 receptor

Cost-Utility Analysis of Lurasidone Versus Aripiprazole in Adults with Schizophrenia

Effectiveness of aripiprazole once-monthly in schizophrenia patients pretreated with oral aripiprazole: a 6-month, real-life non-interventional study

Correction to: Effectiveness of aripiprazole once-monthly in schizophrenia patients pretreated with oral aripiprazole: a 6-month, real-life non-interventional study

Therapeutic reference range for aripiprazole in schizophrenia revised: a systematic review and metaanalysis

Therapeutic Reference Range for Aripiprazole in Schizophrenia Revised: a Systematic Review and Metaanalysis

Therapeutic reference range for aripiprazole in schizophrenia revised: a systematic review and metaanalysis

Treating symptomatic hyperprolactinemia in women with schizophrenia: presentation of the ongoing DAAMSEL clinical trial (Dopamine partial Agonist, Aripiprazole, for the Management of Symptomatic ELevated prolactin)

Evaluation of dopamine D3 receptor occupancy by blonanserin using [11C]-(+)-PHNO in schizophrenia patients

Place of the partial dopamine receptor agonist aripiprazole in the management of schizophrenia in adults: a Delphi consensus study

Differences in autonomic nervous system activity between long-acting injectable aripiprazole and oral aripiprazole in schizophrenia

Relationship between subjective well-being and aripiprazole: an [11C]raclopride PET study

Binding kinetics of cariprazine and aripiprazole at the dopamine D3 receptor

Cost-Utility Analysis of Lurasidone Versus Aripiprazole in Adults with Schizophrenia

Effectiveness of aripiprazole once-monthly in schizophrenia patients pretreated with oral aripiprazole: a 6-month, real-life non-interventional study

Correction to: Effectiveness of aripiprazole once-monthly in schizophrenia patients pretreated with oral aripiprazole: a 6-month, real-life non-interventional study

Therapeutic reference range for aripiprazole in schizophrenia revised: a systematic review and metaanalysis

Therapeutic Reference Range for Aripiprazole in Schizophrenia Revised: a Systematic Review and Metaanalysis

Therapeutic reference range for aripiprazole in schizophrenia revised: a systematic review and metaanalysis

Treating symptomatic hyperprolactinemia in women with schizophrenia: presentation of the ongoing DAAMSEL clinical trial (Dopamine partial Agonist, Aripiprazole, for the Management of Symptomatic ELevated prolactin)

Related objects

Reset password